All In Biotech

Drug Trial Radar · NCT00673387

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects.

Last checked: Nov 20, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 636 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

636

Actual

Start

Apr 2008

Primary completion

Apr 2009

Study completion Oct 2009

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects.

Conditions

  • Overweight
  • Obesity

Interventions

  • pramlintide acetateDrug

    subcutaneous injection, twice a day

  • metreleptinDrug

    subcutaneous injection, twice a day

  • placebo-PDrug

    subcutaneous injection, twice a day

  • placebo-MDrug

    subcutaneous injection, twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable PopulationTime frame: Baseline to Week 28

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Chandler, Arizona

  • Research Site

    Santa Rosa, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Denver, Colorado

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Pembrook Pines, Florida

  • Research Site

    Plantation, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Springfield, Illinois

  • Research Site

    Overland Park, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Auburn, Maine

  • Research Site

    Boston, Massachusetts

  • Research Site

    Edina, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Butte, Montana

  • Research Site

    New York, New York

  • Research Site

    Statesville, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Eugene, Oregon

  • Research Site

    Medford, Oregon

  • Research Site

    Anderson, South Carolina

  • Research Site

    Greer, South Carolina

  • Research Site

    Mt. Pleasant, South Carolina

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Norfolk, Virginia

  • Research Site

    Belingham, Washington

  • Research Site

    Olympia, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.